Treatment of non-small-cell lung cancer in North America: The emerging role of irinotecan

ONCOLOGY

Volumn 15, Issue 1 SUPPL. 1, 2001, Pages 19-24

  Langer, Corey J ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MORTALITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL RATE; UNITED STATES;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE; UNITED STATES;

EID: 0035228293     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Parkin DM, Pisani P, Ferlay J: Global Cancer Statistics, CA Cancer J Clin 49:33-64, 1999.
2. Fukuoka M, Masuda N: Clinical studies of irinotecan alone and in combination with cisplatin. Cancer Chemother Pharmacol 34(suppl):S105-S111, 1994.
3. Fukuoka M, Niitani H, Suzuki A, et al: A phase II study of CPT-11, a new derivative of camptothecin for previously untreated non-small cell lung cancer. J Clin Oncol 10:16-20, 1992.
4. Negoro S, Fukuoka M, Masuda N, et al: A phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin in the treatment of non-small cell lung cancer. J Natl Cancer Inst 83:1164-1168, 1991.
5. Douillard JY, Ibrahim N, Riviere A, et al: A phase II study of CPT-11 in non-small cell lung cancer (abstract 1118). P roc Am Soc Clin Oncol 14:365a, 1995.
6. Baker L, Khan R, Lynch T, et al: Phase II study of irinotecan in advanced NSCLC (abstract 1650). Proc Am Soc Clin Oncol 16:461a, 1997.
7. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311:899-909, 1995.
8. Albain KS, Crowley JJ, LeBlanc, et al: Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol 9:1618-1626, 1991.
9. Masuda N, Fukuoka M, Fujita A, et al: A phase II trial of combination of CPT-11 and cisplatin for advanced non-small cell lung cancer. Br J Cancer 78:251-256, 1998.
10. Ueoka H, Kiura K, Hireki S, et al: Fractionated administration of cisplatin and irinotecan in patients with stage IIIB and IV non-small cell lung cancer: A phase II study (abstract 2026). Proc Am Soc Clin Oncol 18:525a, 1999.
11. Masuda N, Fukuoka M, Nagoro S, et al: A randomized trial comparing cisplatin and irinotecan vs cisplatin and vindesine vs CPT-11 alone in advanced non-small cell lung cancer (NSCLC): A multicenter phase III study (abstract 1774). Proc Am Soc Clin Oncol 18:459a, 1999.
12. Wozniak AJ, Crowley JJ, Balcerzak SP, et al: Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: A Southwest Oncology Group Study. J Clin Oncol 16:2459-2465, 1998.
13. Bonomi P, Kim K, Fairclough D, et al: Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group (ECOG) trial. J Clin Oncol 18:623-631, 2000.
14. Niho S, Nagao K, Nishiwaki Y, et al: A randomized multicenter phase III trial of irinotecan and cisplatin vs cisplatin and vindesine in patients with advanced non-small cell lung cancer (abstract 1897). Proc Am Soc Clin Oncol 18:429a, 1999.
15. DeVore RF, Johnson DH, Crawford J, et al: A phase II study of irinotecan plus cisplatin in patients with advanced non-small cell lung cancer. J Clin Oncol 17:2710-2720, 1999.